ArticleOncotarget2016
KIF23 is an independent prognostic biomarker in glioma, transcriptionally regulated by TCF-4.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- mRNA markers for survival prediction in glioblastoma multiforme patients: a systematic review with bioinformatic analyses.BMC cancer · 2024Pooled it
- Kinesins in Cancer Drug Resistance: Mechanisms, Therapeutic Targeting, and Translational Potential.Cancers · 2026Review
- KIF23 in disease pathogenesis and therapeutics : from molecular mechanisms to clinical translation.Cancer cell international · 2026Review
- KIF23 in disease pathogenesis and its therapeutic and diagnostic potential.Discover oncology · 2026Review
- Decoding the Role of Kinesin Superfamily Proteins in Glioma Progression.Journal of molecular neuroscience : MN · 2025Review
- Research progress of kinesin family in neurological diseases.Frontiers in cellular neuroscience · 2025Review
- KCNQ1OT1 promotes retinoblastoma progression by targeting miR-339-3p that suppresses KIF23.International ophthalmology · 2023Article
- Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients.Genomics, proteomics & bioinformatics · 2021Article
- ESPL1 Is a Novel Prognostic Biomarker Associated With the Malignant Features of Glioma.Frontiers in genetics · 2021Article
- Article
- Mutation and Copy Number Alterations Analysis of KIF23 in Glioma.Frontiers in genetics · 2021Article
- Integrative analyses of gene expression profile reveal potential crucial roles of mitotic cell cycle and microtubule cytoskeleton in pulmonary artery hypertension.BMC medical genomics · 2020Article
- Transcriptome sequencing profiles of cervical cancer tissues and SiHa cells.Functional & integrative genomics · 2020Article
- Identification of Metastasis-Associated Biomarkers in Synovial Sarcoma Using Bioinformatics Analysis.Frontiers in genetics · 2020Article
- Identification of KIF23 as a prognostic signature for ovarian cancer based on large-scale sampling and clinical validation.American journal of translational research · 2020Article
- LINC00174 is a favorable prognostic biomarker in glioblastoma via promoting proliferative phenotype.Cancer biomarkers : section A of Disease markers · 2020Article
- Methylation-mediated repression of MiR-424/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23.Cell cycle (Georgetown, Tex.) · 2019Article
- Integrative analysis of KIF4A, 9, 18A, and 23 and their clinical significance in low-grade glioma and glioblastoma.Scientific reports · 2019Article
- Kinesin family member 20B regulates tongue cancer progression by promoting cell proliferation.Molecular medicine reports · 2019Article
- Novel Biomarkers Associated With Progression and Prognosis of Bladder Cancer Identified by Co-expression Analysis.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kinesin family member 23 (KIF23), a nuclear protein and a key regulator of cellular cytokinesis, has been found to be overexpressed as an oncogene in glioma. However, the prognostic and clinicopathological features of glioma with KIF23 expression was not clear yet. Here, we analyzed KIF23 expression pattern by using whole genome mRNA expression microarray data from Chinese Glioma Genome Atlas (CGGA) database (http://www.cgga.org.cn), and found that KIF23 overexpression was significantly associated with high grade glioma as well as the higher mortality in survival analysis (log-rank test, p<0.01). The results of the three other validation datasets showed similar findings. Furthermore, KIF23 also served as an independent prognostic biomarker in glioma patients. Finally, functional assay showed that reduction of KIF23 suppressed glioma cell proliferation both in vivo and vitro. Additionally, we found that KIF23 was regulated by TCF-4 at transcriptionally level. Therefore, this evidence indicates KIF23 over-expression is associated with glioma malignancy and conferred a worse survival time in glioma, which suggests KIF23 is a new novel prognostic biomarker with potential therapeutic implications in glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.